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Abstract
The HIV envelope glycoprotein gp120 contains nine disulphide bridges and is highly glyco-
sylated, carrying on average 24 N-linked glycans. Using a probability calculation, we here
demonstrate that there is a co-localization of disulphide bridges and N-linked glycans in
HIV-1 gp120, with a predominance of N-linked glycans in close proximity to disulphide brid-
ges, at the C-terminal side of the involved cysteines. Also, N-glycans are frequently found
immediately adjacent to disulphide bridges in gp120 at the N-terminal side of the involved
cysteines. In contrast, N-glycans at positions close to, but not immediately neighboring dis-
ulphide bridges seem to be disfavored at the N-terminal side of the involved cysteines.
Such a pronounced co-localization of disulphide bridges and N-glycans was also found for
the N-glycans on glycoprotein E1 of the hepatitis C virus (HCV) but not for other heavily gly-
cosylated proteins such as E2 from HCV and the surface GP from Ebola virus. The potential
functional role of the presence of N-glycans near disulphide bridges in HIV-1 gp120 was
studied using site-directed mutagenesis, either by deleting conserved N-glycans or by
inserting new N-glycosylation sites near disulphide bridges. The generated HIV-1NL4.3
mutants were subjected to an array of assays, determining the envelope glycoprotein levels
in mutant viral particles, their infectivity and the capture and transmission efficiencies of
mutant virus particles by DC-SIGN. Three N-glycans located nearby disulphide bridges
were found to be crucial for the preservation of several of these functions of gp120. In addi-
tion, introduction of new N-glycans upstream of several disulphide bridges, at locations
where there was a significant absence of N-glycans in a broad variety of virus strains, was
found to result in a complete loss of viral infectivity. It was shown that the N-glycan environ-
ment around well-defined disulphide bridges of gp120 is highly critical to allow efficient viral
infection and transmission.
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Introduction
The envelope of the human immunodeficiency virus (HIV) carries two virus-encoded glyco-
proteins: the surface gp120 and the non-covalently associated transmembrane gp41. The for-
mer is highly glycosylated, carrying 18 to up to 32 N-linked glycans (24 on average) which
occur clustered on the protein and constitute about 50% of the molecular weight of gp120 [1–
3]. Although still subject of discussion, it is nowadays assumed that at least 56–73% of these N-
linked glycans on gp120 are high-mannose-type glycans [4], which is unusual as compared to
cellular glycoproteins containing mostly, if not exclusively, complex-type glycans [5]. In addi-
tion to N-glycans, gp120 is also characterized by 18 cysteines which form 9 disulphide bridges.
It has been shown that 5 disulphide bridges are crucial for the correct folding of gp120 and six
or seven of the disulphide bridges in gp120 are found to be indispensable for appropriate enve-
lope function [6].
During glycoprotein biosynthesis, N-glycosylation and disulphide bridge formation in the
endoplasmic reticulum (ER) are considered to have a reciprocal influence on each other. N-
glycans may sterically hinder the formation of disulphide bridges [7] and disulphide bridges in
turn may prevent the use of a nearby N-glycosylation site [8]. Normally, the addition of N-
linked glycans to the asparagine of an N-glycosylation motif (Asn-X-Thr/Ser, in which X is not
proline) by the ER oligosacharyl transferase in the nascent protein backbone initiates the recog-
nition of glycoproteins by the ER resident lectins calreticulin and calnexin. These lectins act as
chaperones and enhance folding of glycoproteins by the recruitment and activation of the dis-
ulphide isomerase ERp57, which is responsible for the formation of disulphide bridges in gly-
coproteins (reviewed in [9]). Together, calnexin, calreticulin and ERp57 are responsible for the
correct folding of the HIV precursor envelope glycoprotein gp160 in the ER, after which it is
cleaved to gp120 and gp41 in the Golgi apparatus (reviewed in [10]).
By inspecting the structure of HIV-1NL4.3 gp120, we noticed that more than half of the
disulphide bridges are immediately surrounded by N-linked glycans (Fig 1). These observations
may suggest that the presence of N-glycans immediately near, or close to the disulphide
bridges in gp120 is not a coincidence and that there might exist a specific functional interfer-
ence between the location of disulphide bridges and these N-linked glycosylation sites in HIV
gp120.
Given the important role of disulphide bridges and N-glycans during glycoprotein biosyn-
thesis, we wondered whether neighboring disulphide bridges and N-glycans could have a cen-
tral, indispensable role in gp120 biosynthesis and functionality. To address this issue, the
distribution and appearance of neighboring disulphide bridges and N-glycans in gp120 was
first investigated using an alignment of a wide variety of different HIV-1 subtypes. Next, a
broad variety of mutant HIV-1NL4.3 strains lacking disulphide bridges and/or the neighboring
N-glycans in gp120 was generated. In addition, new N-glycosylation sites were introduced in
HIV-1NL4.3 gp120 at positions that were found to be disfavored for glycosylation in wild-type
(WT) gp120. We examined the influence of these mutations on the biosynthesis and function-
ality of gp120 to explore the importance of neighboring disulphide bridges and N-glycans in
HIV-1 gp120.
Materials and Methods
Probability calculations for co-localization of disulphide bridges and N-
glycosylation sites in HIV gp120
The position, number and level of conservation of disulphide bond-engaged cysteines in HIV-
1 gp120 was determined. Therefore, the HIV Env sequence compendium (2014) available on
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Fig 1. Schematic structure of HIV-1NL4.3 gp120 with indication of theN-glycans and disulphide bridges that were deleted/inserted using site-
directedmutagenesis.Disulphide bridges that were found in close proximity to one or two N-glycosylation sites, either directly neighboring or separated
from each other by one other amino acid, are indicated with a red circle. Disulphide bridges that are not directly neighbored by N-glycans are indicated by a
green circle. Mutations resulting in deleted disulphide bridges (Cys!Ala) or N-glycosylation sites (Asn!Gln) are indicated in black. Mutations resulting in the
generation of novelN-glycosylation sites, due to the introduction of an Asn-X-Ser motif, are indicated in blue (only the glycosylated Asn is shown). The N-
terminal signal sequence is colored in white, the conserved domaines (C1–C5) in light grey and the variable loops (V1–V5) in dark grey. Cysteines that are
involved in a disulphide bridge are colored black. Figure based on Leonard et al. [3]. Amino acid numbering according to HIV-1 strain HXB2.
doi:10.1371/journal.pone.0130621.g001
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the HIV sequence database website [11] was consulted. The level of conservation of the disul-
phide bond-engaged cysteines was determined by calculating the occurrence of these cysteines
in 180 HIV-1 sequences of HIV-1 strains belonging to group M (including group M recombi-
nants) [11]. In total, 18 disulphide bond-engaged cysteines were found in HIV-1 gp120 and all
were at least 98% conserved (S1 Table).
Next, the positions of N-linked glycosylation sites in HIV-1 gp120 were determined using
the N-glycosite software available on the HIV sequence database website [11], based on an
alignment of consensus sequences (2004) [11]. The alignment contained consensus sequences
for HIV-1 subtypes A1, A2, B, C, D, F1, F2, G, H, CRF01-AE, CRF02-AG, CRF03-AB,
CRF04-cpx, CRF06-cpx, CRF08-BC, CRF10-CD, CRF11-cpx, CRF12-BF, and CRF14-BG. The
consensus of consensus sequences and the ancestral sequences were excluded from the analysis.
For the calculations, a distinction was made between N-glycosylation sites with at least 50%
conservation (24 N-glycosylation sites) and N-glycosylation sites with less than 50% conserva-
tion (33 N-glycosylation sites). The frequency of the actual occurrence of conserved and non-
conserved N-glycans at a distance of 1, 2, 3, 4 or 5 amino acids away from a cysteine involved
in a disulphide bridge was calculated and compared to the frequency that could be expected in
case of random distribution of 24 conserved and 33 non-conserved N-glycans across gp120.
We made a distinction between the N-glycans at the N-terminal side and at the C-terminal side
of the cysteine. For a more elaborate clarification of these calculations, the supplementary S2
Table should be consulted.
Similar calculations were also performed for the envelope glycoproteins of Ebola virus and
hepatitis C virus (HCV). Sequence information was obtained from the NCBI database [12]:
UniProtKB codes (Q05320.1) and (O11457.1) for Ebola GP; GenBank ID (ABC40379.1) for
HCV E1 and NCBI Reference Sequence (NP_751921.1) for HCV E2. The allocation of N-gly-
cosylation sites and disulphide bridges in GP, E1 and E2 was based on publications of Jeffers
et al. [13], Wahid et al. [14] and Krey et al. [15] respectively.
Cells
Human embryonic kidney cells (HEK293T) were obtained from the American Type Culture
Collection (ATCC) (Manassas, VA) and were grown in Dulbecco’s Modified Eagle Medium
(DMEM) (Invitrogen, Merelbeke, Belgium), supplemented with 10% fetal calf serum (FCS)
(Sigma, Bornem, Belgium), 75 mM NaHCO3 and 2% gentamicin (Invitrogen).
Human CD4+ T lymphocytic C8166 cells were obtained from ATCC. Human B lympho-
cytic Raji/DC-SIGN cells, expressing dendritic cell-specific intercellular adhesion molecule-
3-grabbing non-integrin (DC-SIGN), were constructed by Geijtebeek et al. [16] and kindly
provided by Dr. L. Burleigh (Institut Pasteur, Paris, France). These cell lines were both grown
in RPMI-1640 medium (Invitrogen), supplemented with 10% FCS (Sigma), 75 mM NaHCO3,
2 mM L-glutamine and 2% gentamicin (Invitrogen).
Site-directed mutagenesis
Mutations were introduced into the plasmid pBlue_Env [17], encoding the precursor envelope
glycoprotein gp160 of HIV-1NL4.3. Mutagenesis was achieved using the Quikchange Site-
Directed Mutagenesis Kit (Agilent Technologies, Diegem, Belgium) and the primers listed in
S3 Table. Plasmid DNA was purified with the PureLink Quick Plasmid Miniprep Kit (Invitro-
gen) and sequenced with the ABI PRISM BigDye Terminator v3.1 Ready Reaction Cycle
Sequencing Kit (Applied Biosystems, Ghent, Belgium) to confirm the presence and identity of
the desired mutations. The obtained amplicons were loaded onto the ABI3100 Genetic
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Analyzer (Applera, Nieuwekerk a/d Issel, The Netherlands) after which the sequences were
analyzed using the Geneious Pro 5.5.6 software.
The oligonucleotide sequences of all primers, of which some have been published before
[18], are listed in S3 Table. The different mutations that were introduced into HIV-1NL4.3
gp120 are presented in Fig 1 and listed in S4 Table.
Viruses
HIV-1NL4.3 was recombinantly produced as described previously [19]. Briefly, HEK293T cells
were cotransfected with a PCR product encoding gp160 and pNL4.3_ΔEnv_eGFP linearized by
XbaI-digestion. This results in homologous recombination, inserting the gp160 gene in the
pNL4.3_eGFP backbone. Therefore, transfected and infected cells express enhanced green fluo-
rescent protein (eGFP). The construct pNL4.3_ΔEnv_eGFP was kindly provided by Dr. M.E.
Quiñones‐Mateu (Lerner Research Institute, Cleveland, OH, USA) [20].
HIV-1NL4.3 lacking envelope glycoproteins was produced by transfecting the construct
pNLHIVxΔUΔss into HeLa-tat-III cells using GeneCellIn (BioCellChallenge, Nivelles, Bel-
gium), according to the instructions of the manufacturer. The construct pNLHIVxΔUΔss, was
a kind gift from Dr. Alenka Jejcic (at that time at the Karolinska Institute, Stockholm, Sweden).
Western blotting to evaluate Env incorporation in viral particles
To determine the expression and subsequent incorporation of the envelope glycoproteins
gp120 and gp41 in viral particles, virus concentrates equaling 50 ng of p24 capsid protein were
loaded onto a 4–12% Bis-Tris PAGE gel (Invitrogen). After blotting to a PVDF membrane (GE
healthcare life sciences, Diegem, Belgium), gp120, gp41 and p24 were detected with the respec-
tive antibodies: PAI-7218 (Thermo Scientific, Erembodegem, Belgium), C8 and AB9044
(Abcam, Antwerp, Belgium). The monoclonal antibody directed to gp41, C8, was derived from
HIV-1 gp41 Hybridoma (Chessie 8) cells and obtained through the NIH AIDS Reagent Pro-
gram, Division of AIDS, NIAID, NIH, from Dr George Lewis [21]. Visualization was achieved
by using secondary, horse radish peroxidase (HRP)-labelled antibodies, the SuperSignal West
Pico Chemiluminescent Substrate kit (Thermo Scientific, Erembodegem, Belgium) and Image
Lab (BioRad).
Evaluation of the infectivity of the mutant virus strains
106 C8166 cells were brought into wells of a 24-well plate at day 0 and infected with 40 ng p24
of wild-type (WT) or mutant HIV-1NL4.3. By adding RPMI-1640 culture medium it was ascer-
tained that every well contained a total volume of 2 ml. Every day for 7 following days, cell cul-
ture samples were harvested and fixed in 3% formaldehyde. At the end, the percentage of
infected cells was quantified for all samples by the analysis of eGFP expression upon infection
with a FACS CantoII flow cytometer (Becton Dickinson, San Jose, CA). The data were analysed
by FACS Diva Software (Becton Dickinson).
Capture of HIV-1NL4.3 particles by Raji/DC-SIGN cells
Wild-type and mutant HIV-1NL4.3 strains (equivalents of 25 ng p24) were incubated with 10
6
Raji/DC-SIGN cells for 1h at 37°C. Afterwards, the cells were washed thoroughly to eliminate
unbound virions. The cells were then resuspended in 1ml of fresh culture medium, after which
the concentration of the viral capsid protein p24 was quantified using a p24 enzyme-linked
immunosorbent assay (ELISA) (PerkinElmer, Boston, MA), to quantify the amount of virus
particles captured by the Raji/DC-SIGN cells. The virus capture efficiency was defined as the
Co-Localization of N-Glycans and C-C Bridges in HIV-1 gp120
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amount of DC-SIGN-captured virions per 10 ng p24 used during virus exposure to the cells,
and expressed relative to WT virus.
Transmission of captured virus from Raji/DC-SIGN to CD4+ T
lymphocyte C8166 cells
Raji/DC-SIGN cells (2 x 105) were exposed to WT or mutant HIV-1NL4.3 particles (equiva-
lents of 5 ng p24) during 1h at 37°C. After thoroughly washing to eliminate unbound virions,
the (virus-bound) cells were resuspended in 200μl of fresh culture medium. Next, the virus-
bound Raji/DC-SIGN cells were exposed to 2 x 105 C8166 cells in a total volume of 1 ml. Fol-
lowing an incubation of 72h, samples were harvested to quantify the amount of HIV-1 p24
antigen using a p24 ELISA (PerkinElmer). These values were used as a measure of viral pro-
duction resulting from transmission of virions from virus-captured Raji/DC-SIGN cells to
CD4+ C8166 cells.
Statistics
A Student’s t-test was used to validate the significance of the data. A p value<0.05 was consid-
ered as significant.
Results
Several highly conserved N-linked glycans of gp120 are preferentially
localized near disulphide bridges
Out of the 9 highly conserved disulphide bridges in gp120 of HIV-1NL4.3, four were found to
contain at least 1 N-linked glycan on an asparagine directly neighboring one of the involved
cysteines and at one of those four locations, both cysteines of the disulphide bridge were
located directly next to a glycosylated asparagine. Besides these four cysteine bridges, one other
disulphide bridge was found to be located near 2 glycosylated asparagines that were separated
from the cysteines by only one other amino acid (Fig 1).
An alignment of HIV-1 Env amino acid sequences was used to check the occurrence of
neighboring disulphide bridges and N-glycans across gp120 belonging to a wide variety of
HIV-1 strains. The alignment was obtained from the HIV sequence database [11], and the N-
glycosylation sites in HIV-1 gp120 among 19 HIV-1 subtypes (including more than 200 indi-
vidual strains) were determined. A distinction was made between N-glycosylation sites with at
least 50% conservation and N-glycosylation sites with less than 50% conservation. A total of
24 conserved and 33 non-conserved N-glycosylation sites were found in HIV-1 gp120. Next,
the probability of finding a conserved or non-conserved N-glycan at a distance of 1, 2, 3, 4 or 5
amino acids away from a disulphide bridge was calculated in case of random distribution of
the N-glycans across gp120 (probability 1.0 at the ordinate of the distribution diagram, repre-
sented by the dashed horizontal line) (Fig 2A and 2B). These data were compared to the actual
observed frequencies. It was found that the chance of finding a conserved N-glycan at an
asparagine directly neighboring a cysteine which is involved in a disulphide bridge in gp120
(both at the N-terminal and the C-terminal side of the cysteine) was about 3.3 times greater
than in the case of random distribution of the conserved N-glycans across gp120 (Fig 2A). At
the N-terminal side, it was striking to notice that there are no conserved glycans at a distance
of -2, -3, -4 or -5 amino acid positions from a disulphide bridge. The complete absence of an
N-glycan at position -2 is expected because this is inherent to the obligate N-X-S/T N-glycosyl-
ation motif excluding an N-glycan 2 amino acids upstream of a cysteine. In contrast, the
absence of conserved N-glycans at positions -3, -4 and -5 was not obvious and hence
Co-Localization of N-Glycans and C-C Bridges in HIV-1 gp120
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Fig 2. Probability of finding anN-linked glycosylation site at a position 1–5 amino acids from a disulphide bridge in gp120. The positions and levels
of conservation of N-linked glycosylation sites in HIV-1 gp120 were determined using the N-glycosite software available on the HIV sequence database
website [11], based on an alignment of consensus sequences of 19 HIV-1 subtypes (2004) [11]. The probability of findingN-glycosylation sites closeby
cysteines involved in disulphide bridges was calculated. The graph shows the relative probabilities of a glycosylated asparagine at 1, 2, 3, 4 or 5 amino acid
positions away from the cysteines involved in disulphide bridges. Negative amino acid positions correspond to positions at the N-terminal site of the cysteine,
positive amino acid positions correspond to positions at the C-terminal site of the cysteine. The cysteine itself is shown as a black bar. The striped line
indicates the probablities in case of random distribution of N-glycosylation sites. (A) N-glycosylation sites with at least 50% conservation. (B) N-glycosylation
sites with less than 50% conservation.
doi:10.1371/journal.pone.0130621.g002
Co-Localization of N-Glycans and C-C Bridges in HIV-1 gp120
PLOS ONE | DOI:10.1371/journal.pone.0130621 June 29, 2015 7 / 24
unexpected (Fig 2A). At the C-terminal side, there is a preference for N-glycosylation, espe-
cially at positions +1 and +3 (frequency 3.3 to 2.2 times higher than in case of random distri-
bution). It could therefore be concluded that several conserved N-glycans of gp120 show a
predominant localization near disulphide bridges, especially at the -1 amino acid position on
the N-terminal side and the +1 and +3 amino acid positions at the C-terminal side of the cyste-
ine, and that the complete absence of a conserved N-glycan at amino acid positions -3, -4, -5
and +4 was rather unexpected. Moreover, similar calculations were also performed for the
non-conserved N-glycans of gp120. It was found that non-conserved glycans showed a less
pronounced co-localization with disulphide bridges, except for the +4 amino acid position
with respect of the involved cysteines (frequency at +4 position 2.4 times higher than in case
of a random distribution) (Fig 2B). Although non-conserved glycans were observed at the -5
position with respect of disulphide bond-engaged cysteines, again no glycans were found at
the -4 and -3 amino acid positions (Fig 2B).
For comparative reasons, similar calculations were also performed for other (highly N-
glycosylated) envelope glycoproteins such as those of Ebola virus and HCV. For Ebola GP, not
a single N-glycosylation site was found within a distance of 5 amino acids from a cysteine that
was involved in a disulphide bridge, neither on the N-terminal or on the C-terminal side of the
cysteines. Instead, for both envelope glycoproteins of HCV (E1 and E2) we found multiple N-
glycans in proximity of disulphide bridges (S1 Fig). Although the co-localization of disulphide
bridges and N-glycans was only modest for HCV E2, the phenomenon was more pronounced
for HCV E1. In addition, for both E1 and E2 we observed more N-glycans at the first five posi-
tions near the C-terminal side of disulphide bridges, as compared to the N-terminal side. Thus,
the pattern of N-glycan clustering near disulphide bridges in viral glycoproteins is not limited
to HIV-1 gp120 on the one hand, but is not a general phenomenon either among viral
glycoproteins.
Site-directed mutagenesis of cysteines and neighboring N-glycosylation
sites in HIV-1 gp120
In an attempt to reveal the function of disulphide bridges and the nearby N-glycans, site-
directed mutagenesis on HIV-1NL4.3 gp120 was performed to mutate cysteines involved in
these disulphide bridges, and to insert or eliminate N-glycosylation sites within a distance of 1
to 5 amino acids away from these cysteines (Fig 1 and S4 Table). For the elimination of disul-
phide bridges, one of the involved cysteines was mutated into an alanine. Deletion of N-glycans
was achieved by mutating the asparagine which is part of the N-glycosylation motif into a glu-
tamine. The insertion of new N-glycosylation sites was obtained by the introduction of an
asparagine, 2 amino acids upstream of a newly introduced serine.
Fig 1 shows the location of the different mutations in HIV-1NL4.3 gp120. In total, 5 cysteines
(red circles) and 7 asparagines (black arrows) were mutated, as well as combinations of both
the cysteine and its neighboring asparagine(s). In addition, 6 new N-glycosylation sites (blue
arrows) were introduced in the proximity of 2 disulphide bridges, either instead of, or in com-
bination with, the N-glycosylation site that neighbors these cysteines in WT gp120.
Fig 3 represents the alignment of HIV-1 gp120, obtained from the HIV sequence database
[11], with indication of the N-glycans that were deleted using site-directed mutagenesis (verti-
cal black lines with amino acid numbering). It was shown that 6 out of the 7 deleted N-glycans
were at least 75% conserved [4 were fully (100%) conserved (i.e. N156, N197, N241 and N386),
one was 88% conserved (i.e. N332) and the other N-glycosylation site was 75% conserved (i.e.
N295)]. In contrast, the glycan on N230 which is present in HIV-1NL4.3 and included in our
study, was only 17% conserved among all strains in the HIV sequence database [11].
Co-Localization of N-Glycans and C-C Bridges in HIV-1 gp120
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Effect of disulphide bridge or N-glycan deletions on the envelope
glycoprotein levels in mutant viral particles
To investigate the role of the co-localization of disulphide bridges and N-glycans in gp120 of
HIV-1NL4.3, WT virus was compared to mutant viruses in which either the disulphide bridge,
the nearby N-glycosylation site or both were mutated. First, the effect of these mutations on
envelope glycoprotein biosynthesis and subsequent incorporation in the envelope of the viral
particles was examined using western blotting on lysates of WT and mutant virus strains.
It was shown that the disruption of the disulphide bridges by mutating one of its cysteines
markedly abrogated (by 75 to>95%) incorporation of both gp120 and gp41 in the virus parti-
cles (Fig 4A and 4C). In contrast, most of the N-glycan deletions did not markedly reduce enve-
lope glycoprotein expression and incorporation in the viral particle (Fig 4B and 4D). Only the
mutation N156Q in gp120 resulted in a substantial decrease of gp120 (by* 60%) and gp41
(by* 75%) levels in the viral envelope.
It could be concluded that deletion of a disulphide bridges had a much more dramatic influ-
ence on the eventual incorporation of gp120 and gp41 in the virus particles, as compared to the
deletion of the neighboring N-glycans.
Fig 3. HIV-1 gp120 amino acid alignment with indication of N-glycosylation sites that were mutated in this study. An alignment of consensus
sequences (2004) of the amino acid sequence of gp120 was obtained through the HIV sequence database [11] and was analyzed with the N-glycosite
software [11] to locate N-glycosylation sites. For our analysis, we did not include the consensus of consensus sequences nor the ancestral sequences, but
focused on the consensus sequences for HIV-1 subtypes A1, A2, B, C, D, F1, F2, G, H, CRF01-AE, CRF02-AG, CRF03-AB, CRF04-cpx, CRF06-cpx,
CRF08-BC, CRF10-CD, CRF11-cpx, CRF12-BF, and CRF14-BG. The height of the bars indicates the level of conservation among these HIV-1 subtypes.
The 7 black bars represent N-glycosylation sites that were found in HIV-1NL4.3 gp120 to be located near a disulphide bridge (directly neighbouring one of the
disulphide cysteines or separated by only one amino acid) and were mutated by site-directed mutagenesis.
doi:10.1371/journal.pone.0130621.g003
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Disulphide bridges or N-glycan deletions have a variable effect on viral
infectivity
Next, the influence of the deletion of disulphide bridges and/or their neighboring N-glycans
was determined on viral infectivity. Therefore, WT and mutant HIV-1NL4.3 were exposed to
susceptible CD4+ T cells for an extended time period. Each day, part of the cell cultures were
harvested and viral infection was quantified based on eGFP expression in the infected cells. As
could be predicted from the western blot analysis of the gp120/gp41 levels in the mutant
viruses, those mutant virus strains lacking one of the disulphide bridges in gp120 virtually
completely lost their infectivity potential (Fig 5A). The effect of the deleted neighboring N-
glycans on virus infectivity was dependent on the particular location of the deleted N-glycans
Fig 4. Western blot analysis of envelope glycoprotein incorporation in WT andmutant virus particles. Virus was concentrated, lysed and subjected to
western blotting. Gp120, gp41 and p24 were detected in virus lysates of (A) mutants lacking a disulphide bridge and (B)N-glycosylation site mutants. (C-D)
Quantification of protein levels was performed using the BioRad Image Lab Software, based on panels A and B. Gp160, gp120 and gp41 levels are
presented after normalization to the p24 levels. Graphs represent the mean ± SEM based on 2–4 independent experiments. The difference betweenWT and
mutant virus was considered to be significant when the p value calculated using the student’s t-test was <0.05 (* = p<0.05, for both gp120+gp160 and gp41).
doi:10.1371/journal.pone.0130621.g004
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(Fig 5B and 5C). For example, the gp120 mutations N197Q and in particular N156Q resulted
in a markedly decreased viral infectivity, relative to WT virus. Gp120 mutations N332Q and
N386Q also showed decreased viral infectivity, although less pronounced. Instead, the gp120
mutations N230Q, N241Q and N295Q were shown to have an enhancing effect on viral infec-
tion, as compared to WT virus.
Deletion of a disulphide bridge, but not a nearby N-glycan, markedly
affects virus capture efficiency by DC-SIGN
Not only infectivity as such, but also the capacity of HIV to be efficiently captured by DC-SIGN
and its subsequent transmission to susceptible cells is important during in vivo viral infection.
DC-SIGN is a lectin of the innate immune system that is present on dendritic cells and recog-
nizes high-mannose-type glycans on pathogen targets such as HIV gp120 [16, 22]. The deletion
of a high-mannose-type glycan on gp120 can potentially influence the capability of DC-SIGN+
cells to capture mutant virus particles. To explore this hypothesis, WT and mutant virus parti-
cles were exposed to Raji/DC-SIGN cells during one hour, after which the cells were washed
thoroughly to eliminate unbound virions. The amount of captured virus was then quantified
using a p24 ELISA. It was shown that the deletion of a disulphide bridge resulted in a marked
decrease in the capture efficiency (30–81% decrease), as compared to WT virus (Table 1, left
part). Instead, Table 1 (right part) reveals that the deletion of an N-linked glycan located in
very close proximity of a disulphide bridge in most cases did not markedly reduce the capture
efficiency by DC-SIGN, as compared to WT virus. Interestingly, the mutations N197Q and
N295Q in gp120 even increased the capacity of the mutant viruses to become captured by Raji/
DC-SIGN cells.
Effect of disulphide bridge or N-glycan deletions on transmission of
DC-SIGN-captured virus particles
When virus-captured Raji/DC-SIGN cells are brought into contact with CD4+ T lymphocyte
cells, virus is efficiently transmitted from the Raji/DC-SIGN cells to the susceptible CD4+ T
cells, which are subsequently infected and produce new viral particles [16]. The efficiency of
Fig 5. Infectivity of WT andmutant gp120 HIV-1 strains. At day 0, CD4+ T lymphocyte C8166 cells were infected with similar viral loads of WT or mutant
virus strains, based on equal amounts of the p24 capsid protein. For 7 consecutive days, samples were harvested, fixed and subjected to flow cytometry to
analyse eGFP expression. (A) Infectivity of mutant viruses lacking disulphide bridges in gp120, due to the mutation of one of the involved cysteines into an
alanine. (B) Infectivity of mutant viruses lacking oneN-glycosylation site in gp120 due to the mutation of the asparagine of the glycosylation motif into a
glutamine. (C) The infectivity as shown in panel B was quantified using a linear regression to part of the curves, from day 1 post infection to the peak of the
infectivity curve. Data are the means ± SEM of at least 2 independent experiments. The difference betweenWT and mutant virus was considered to be
significant when the p value calculated using the student’s t-test was <0.05 (* = p<0.05).
doi:10.1371/journal.pone.0130621.g005
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viral transmission upon cocultivation of virus-captured Raji/DC-SIGN cells and CD4+ C8166
cells can therefore be quantified by analyzing virion production by the C8166 cells through a
p24 ELISA. The transmission efficiency was normalized to initial equal capture efficiencies (as
determined in the previous section). It was found that the deletion of a disulphide bridge in
HIV-1 gp120 almost completely prevented the viral transmission to uninfected CD4+ cells
(Fig 6A). Interestingly, the glycosylation site mutations N156Q, N197Q and N386Q in gp120
had a dramatic compromising effect on the mutant virus transmission efficiency, as compared
to WT virus. Gp120 mutations N241Q and N332Q were endowed with transmission
Table 1. Capture efficiency of mutant gp120 virus strains, relative to capture efficiency of wild-type
virus.
Virus Relative capture efficiency Virus Relative capture efficiency
C157A 59 ± 3 (*) N156Q 106 ± 7
C196A 70 ± 4 (*) N197Q 167 ± 16
C228A 19 ± 2 (*) N230Q 108 ± 12
C331A 30 ± 7 (*) N241Q 100 ± 7
C385A 46 ± 12 N295Q 130 ± 16
N332Q 91 ± 8
N386Q 93 ± 11
Data are the means ± SEM of at least 2 independent experiments.
The difference between WT and mutant virus was considered to be significant when the p value calculated
using the student’s t-test was <0.05 (* = p<0.05).
doi:10.1371/journal.pone.0130621.t001
Fig 6. Transmission efficiency of wild-type andmutant virus strains. Virus-exposed Raji/DC-SIGN cells were cocultivated with C8166 CD4+ T cells for
72 h. Production of virus particles by the C8166 cells (following transmission of HIV from the virus-captured Raji/DC-SIGN cells) was quantified using a p24
ELISA and was used as a measurement for transmission efficiency. Data were normalized to capture efficiency and presented as relative to transmission of
WT virus. Data are the means ± SEM of at least 2 independent experiments. The difference betweenWT and mutant virus was considered to be significant
when the p value calculated using the student’s t-test was <0.05 (* = p<0.05).
doi:10.1371/journal.pone.0130621.g006
Co-Localization of N-Glycans and C-C Bridges in HIV-1 gp120
PLOS ONE | DOI:10.1371/journal.pone.0130621 June 29, 2015 12 / 24
efficiencies comparable to WT virus. In contrast, gp120 mutations N230Q and N295Q resulted
in increased virus transmission (Fig 6B).
Correlation between viral infectivity and transmission efficiency for
mutant viruses with N-glycan deletions in gp120
It could be assumed that there would be a close correlation between the effect of gp120 N-
glycan deletions on viral infectivity and transmission efficiency, since both processes involve
the interaction between gp120 and CD4/CXCR4/CCR5, require conformational changes in
gp120 upon interaction with CD4/CXCR4/CCR5 and result in membrane fusion. Whereas the
majority of the N-glycan-deleted virus mutants showed a decreased infectivity and a decreased
transmission efficiency (N156Q, N197Q, N332Q, N386Q), two virus mutants (N230Q and
N295Q) were endowed with both an increased infectivity and transmission potential (Fig 7).
Interestingly, it looks like most HIV-1 mutants (i.e. N197, N230Q, N241Q and N386) have
consistently a more pronounced deleterious effect on transmission efficiency than on infection
efficiency. This difference in efficiency was most pronounced for the mutant gp120 N386Q
HIV-1 strain that showed an infection potential ~70% of WT virus, while its transmission
potential was only 10% of WT virus (Fig 7).
The effect of newly introduced gp120 N-glycans in proximity of
disulphide bridges on viral function
In Fig 2A, we demonstrated that conserved N-glycans can be preferentially found in close prox-
imity of disulphide bridges in gp120, although some positions (mainly N-terminal of the cyste-
ines: -5, -4 and -3) seem to be excluded for N-glycosylation. When taking into account non-
conserved N-glycans, N-glycans were still absent at positions -4 and -3 with respect of disul-
phide bond-engaged cysteines of gp120 (Fig 2B). To investigate the meaning of the consistent
lack of N-glycans at specific positions in gp120 near disulphide bridges, mutant HIV-1NL4.3
strains were generated in which an N-glycosylation site was inserted in gp120 at those posi-
tions. Thus, N-glycans were inserted at positions -5, -4 and -3, near one of the cysteines
involved in a disulphide bridge (Fig 1 and S4 Table). Next, the influence of these introduced N-
glycans in HIV-1 gp120 on viral infectivity was studied.
Fig 8A shows the effect on viral infectivity of N-glycans that were introduced at the N-termi-
nal side of cysteine 296 that is involved in a disulphide bridge with cysteine 331. In WT gp120,
C296 is flanked by an N-glycan at N295. N-glycosylation sites were introduced in WT gp120
and in gp120 lacking the N295 glycan. As was shown before (Fig 5B and 5C), the deletion of
the N295 glycan did not have a detrimental effect on viral infectivity. The introduction of an
N-glycan at position -5 had no effect on viral infectivity, irrespective of the absence or presence
of the N295 glycan. However, the introduction of an N-glycan at position -4 resulted in a nearly
complete abolishment of viral infectivity. This was found upon the introduction of the glyco-
sylation site in both WT gp120 and in gp120 lacking the N295 glycan. To make sure that the
observed effect on viral infectivity was due to the introduction of an N-glycan and not to the
individual mutations V292N or I294S, both mutations were also introduced separately into
WT gp120. It was found that the sole mutations V292N or I294S had no effect on viral infectiv-
ity. Therefore, we conclude that the loss of viral infectivity of the mutant HIV-1 strains
V292N/I294S and V292N/I294S/N295Q was due to the insertion of a functional N-glycosyla-
tion site at a position in gp120 that is normally highly disfavored for N-glycosylation. An N-
glycan was also introduced at position -3, thereby inevitable deleting the N295 glycan (N295S
mutation). This newly introduced glycosylation site had no effect on viral infectivity.
Co-Localization of N-Glycans and C-C Bridges in HIV-1 gp120
PLOS ONE | DOI:10.1371/journal.pone.0130621 June 29, 2015 13 / 24
One other disulphide bridge in gp120 was selected for the introduction of nearby N-glyco-
sylation sites, namely the C385-C418 disulphide bridge. New N-glycosylation sites were gener-
ated at the N-terminal side of cysteine 385, at amino acid positions -5, -4 and -3. It was found
that these 3 N-glycosylation sites all resulted in the complete loss of viral infectivity of the
mutant virus strains (Fig 8B).
Fig 7. Correlation between the infectivity and transmission efficiency of the gp120N-glycan deletedmutant virus strains, relative to WT virus. The
black dashed line represents a curve where infectivity and transmission would have been equally influenced by the mutations. White quadrant: both
transmission and infectivity are decreased. Full grey quadrant: both transmission and infectivity are increased. Quadrant with horizontal striping: transmission
efficiency is increased while infectivity is decreased. Quadrant with vertical striping: infectivity is increased while transmission efficiency is decreased.
doi:10.1371/journal.pone.0130621.g007
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Together, these data indicate that the absence of N-glycans at positions close to, but
upstream of, disulphide bridges in gp120 is not a simple coincidence since the introduction of
N-glycans at these positions in most cases resulted in the loss of viral infectivity.
Discussion
We observed for HIV-1NL4.3 that many of the disulphide bridges in gp120 co-localize with N-
linked glycans. We confirmed this finding using a large alignment, containing Env amino acid
sequences of ~200 HIV-1 strains belonging to 19 different HIV-1 subtypes [11]. We found a
statistically significant predominance of conserved N-linked glycans directly neighboring a dis-
ulphide bridge, or in close proximity at the C-terminal side of at least one of its cysteines.
Fig 8. Infectivity of mutant HIV-1NL4.3 strains withN-glycosylation sites introduced in gp120 close to, and upstream of, the disulphide-involved
C296 (A) and C385 (B). At day 0, CD4+ T lymphocyte C8166 cells were infected with similar viral loads of WT or mutant virus strains, based on equal
amounts of the p24 capsid protein. For 7 consecutive days, samples were harvested, fixed and subjected to flow cytometry to analyse eGFP expression. The
infectivity was quantified using a linear regression to part of the obtained eGFP-expression curves, from day 1 post infection to the peak of the curve.
Asparagines involved inN-glycosylation sites (N-X-S/T) are coloured red. C296 and C385 are indicated in green. One introduced Asn (V290N) that was not
part of anN-glycosylation site is indicated in bold (A). Data are the mean ± SEM of 2–3 independent experiments. The difference betweenWT and mutant
virus was considered to be significant when the p value calculated using the student’s t-test was <0.05 (* = p<0.05).
doi:10.1371/journal.pone.0130621.g008
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Moreover, no conserved glycans were found in gp120 at positions -5, -4, -3, -2 or +4, in respect
to cysteines involved in a disulphide bridge. Although this could be expected for position -2
due to the nature of the N-glycosylation motif (Asn-X-Ser/Thr, in which X is any amino acid
except a proline and thus, a cysteine at position 0 prevents the appearance of a glycan at posi-
tion -2), the lack of conserved glycans at positions -5, -4, -3 and +4 was rather unexpected.
However, we found non-conserved N-linked glycans at positions -5 and +4 neighboring disul-
phide bridges in gp120, indicating that occasionally, non-conserved glycans may occur at these
positions. For HCV E1, we found a similar predominant correlation between the location of
disulphide bridges and nearby N-glycans as for HIV-1 gp120, a phenomenon being less pro-
nounced for HCV E2. In contrast, we found no co-localization of disulphide bridges and N-gly-
cans at all in the envelope glycoprotein of Ebola virus.
In addition to the probability calculations that were performed for HIV-1 gp120, HCV E1
and E2, and Ebola virus GP, we aimed to perform a similar calculation for glycosylated Influ-
enza A virus heamagglutinin (HA). However, based on Daniels et al. [23], and confirmed by
various HA sequences obtained from the NCBI database [12], the number of N-glycans on
Influenza A virus HA was too limited, as compared to the number of disulphide bridges, to
obtain relevant data on the probability of co-localization of disulphide bridges and N-glycans
in HA. We could conclude that some viral glycoproteins such as HIV-1 gp120 and HCV E1
have a strong preference of encoding an N-glycan near some of its disulphide bridges, a phe-
nomenon that might have a particular reason in those cases (see below).
It should be noticed that the conserved N-glycans that were shown to co-localize with disul-
phide bridges in HIV-1 gp120 are not necessarily 100% conserved. This implies that some
HIV-1 strains or subtypes do not strictly depend on the presence of these N-glycans. However,
when inspecting the positions and levels of conservation of N-glycans across the 19 investigated
HIV-1 subtypes (including recombinants), it is striking that the lack of a particular conserved
N-glycan in strains of one HIV-1 subtype is often associated with the presence of a non-con-
served N-glycan nearby the missing conserved gp120 N-glycan in these strains. One interesting
example of this observation is the glycan at asparagine 340 in the consensus of consensus HIV
Env sequence [11] (position 332 in HIV-1HXB2), which is positioned at the +1 position with
respect of the disulphide bond-engaged cysteine 339. This N-glycan is 84% conserved among
the 19 HIV-1 subtypes included in our alignment, but is absent in subtypes A2, F2 and
CRF01-AE. Interestingly, in these HIV-1 subtypes, a non-conserved glycan is found at the
asparagine 342 position, which is only 2 amino acid positions downstream of asparagine 340.
This suggests that the incomplete conservation of N-glycans of gp120 can be compensated by
non-conserved N-glycans at nearby positions.
Using site-directed mutagenesis, we generated HIV-1NL4.3 mutants either lacking disulphide
bridges and neighboring N-glycans in gp120, or carrying an additional N-glycan at a position
in gp120 that is normally disfavored for N-glycosylation. In total, 5 disulphide bridges and 7 N-
glycosylation sites were mutated, and 6 N-glycosylation sites were newly generated. The effect
of these mutations was then studied using an array of assays evaluating viral function. It was
shown that the deletion of the 5 disulphide bridges that were found in close proximity to one
or more N-glycans ultimately led to a severe decrease in all examined viral functions: envelope
glycoprotein expression, viral infectivity, capture of virus particles by DC-SIGN and transmis-
sion of DC-SIGN-captured virus to T cells. These data are in agreement with the data of Van
Anken et al. [6] who showed that 5 out of the 9 gp120 disulphide bridges were indispensable
for gp120 folding and another 2 disulphide bridges were crucial for the correct function of the
produced gp120. Interestingly, these investigators showed that the deletion of the gp120
C385-C418 disulphide bridge resulted in severe folding deficiencies, although this mutant virus
strain was shown to still have some residual viral infectivity. The 5 disulphide bridges that were
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included in our study were all described by Van Anken et al. [6] as being indispensable (or in
case of C385-C418 at least to some extent) for the functionality of gp120. Three of these disul-
phide bridges (i.e. C228-C239, C296-C331 and C385-C418) were also found to be crucial for
the correct folding and biosynthesis of gp120. In contrast, disulphide bridges C126-C196 and
C131-C157 were reported not to be crucial for gp120 folding. Comparing these data with the
western blot data obtained in our studies, we could partially confirm the findings of Van
Anken et al. [6]. We also found a more pronounced defect on envelope glycoprotein biosynthe-
sis for the disulphide bridges C228-C239, C296-C331 and C385-C418. However, also upon the
disruption of the disulphide bridges C126-C196 and C131-C157 we found substantially
decreased glycoprotein levels in the viral envelope of the mutant virus particles, suggesting that
the lack of these disulphide bridges also resulted in a heavily compromised gp120/gp41 biosyn-
thesis or envelope incorporation into the virus particles. Van Anken et al. [6] investigated
gp160/gp120 biosynthesis using a vaccinia-virus-based expression system, encoding the viral
Env gene. They studied the folding of intracellular pools of gp160/gp120 and the shedding of
gp160/gp120 in the cellular supernatants. However, the incorporation of gp160/gp120/gp41 in
viral particles was not studied before. This suggests that possibly, the deletion of the disulphide
bridges C126-C196 and C131-C157 might indeed enable correct folding (as observed by Van
Anken et al. [6]) but could result in a deficient incorporation of the envelope glycoproteins in
the viral envelope of newly produced virions (as observed in our studies). Furthermore, the
role of the gp120 disulphide bridges has also been studied by others, emphasizing the crucial
importance of most gp120 disulphide bridges for the biosynthesis of gp120 and the infectivity
of the virus [24–25]. Our data confirm the indispensable role of the C126-C196, C131-C157,
C228-C239 and C296-C331 disulphide bridges for the viral functions, as previously reported.
However, we did not find significant residual viral replication for a mutant HIV strain that
lacks the C385-C418 disulphide bridge, which was different from what has been earlier
reported by others [6, 24, 26].
In order to generate HIV-1NL4.3 mutants with deleted disulphide bridges, we mutated one of
the involved cysteines into an alanine, thereby disrupting the particular disulphide bridge. The-
oretically, the loss of only one single cysteine could result in the scrambling of the disulphide
bridges, resulting in a folded (or misfolded) mutant gp120 containing ether (non-native) disul-
phide bridges. However, Van Anken et al. have compared the effect of the single mutation of
one of the disulphide bond-engaged cysteines with the effect of mutating both cysteines, and
obtained highly similar gp120 folding kinetics for both the single and the double mutants [6].
They therefore suggested that non-native disulphide bridges are not readily formed upon the
mutation of only one disulphide bond-engaged cysteine. If non-native disulphide bridges
would occur at all, they were suggested to have a transient nature, breaking down easily during
further oxidative folding of gp120 [6]. This was confirmed by other investigators, who demon-
strated that the connectivity pattern between gp120 cysteines is highly conserved, except for
the disulphide bridges in the V1-V2 region, which occur with variable connectivities [27–28].
HIV-1NL4.3 mutants lacking the N-glycosylation sites neighboring disulphide bridges were
also generated. It was shown that the N156 glycan was the only investigated glycan that was
indispensable for the correct expression/incorporation of the envelope glycoproteins and the
N156, N197 and N386 glycans were found to play an important role for the proper function of
the envelope glycoproteins. Our data largely confirm the results of Wang et al. [29]. They came
to the same conclusions regarding the N156Q and N197Q mutations in HIV-1 gp120. How-
ever, they found a significant decreased envelope gp120 level in N241Q mutated virus, while
we obtained viral gp120 levels that were similar to WT virus. In addition, Wu et al. demon-
strated the requirement of the N156 glycan for the correct formation of the C131-C157
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disulphide bridge during the biosynthesis of gp120 [30], a finding that is in full agreement with
the highly compromised infectivity we observed for the N156Q gp120 mutated virus.
Despite the significantly decreased expression and incorporation of N156Q gp120 in the
envelope of mutant viral particles, the DC-SIGN-mediated capture of the N156Q gp120
mutant virus strain had an efficiency highly comparable to WT virus. Since DC-SIGN-medi-
ated virus capture is dependent on the interaction of DC-SIGN with gp120, these data might
seem contradictory. However, a similar phenomenon was demonstrated before for the N616Q
glycan deletion in gp41 [31]. This glycan deletion resulted in a>85% decrease in HIV envelope
glycoprotein levels in the viral particle, while only moderately (20%) decreasing the DC-SIGN-
mediated capture efficiency [31]. These data therefore suggest that (i) the interaction between
DC-SIGN and gp120 is highly efficient, enabling a WT-like capture efficiency with only a mini-
mal amount of gp120 available for interaction with DC-SIGN, and/or (ii) that the expression
level of gp120 on WT virus particles exceeds the binding capacity of the limited number of
DC-SIGN molecules expressed on dendritic cells.
An in-depth study of the role of the highly conserved N262 glycan of HIV gp120 has previ-
ously been performed, indicating that the deletion of this N-glycan results in a deficient cleav-
age of the mutant gp160 into gp120 and gp41 in the Golgi apparatus [32]. Indeed, structural
data recently obtained by X-ray crystallography demonstrated the central role of the N262 gly-
can in the folding and stabilization of HIV-1 gp120 [33]. Furthermore, it was demonstrated
that the N262-deleted gp160 was targeted for lysosomal degradation, which is in agreement
with the apparent absence of N262-deleted gp160 or gp120 on the viral envelope [32]. It would
therefore also be interesting to study in more detail the biosynthesis of the mutant HIV-1
gp160 or gp120 with a deleted N156 glycosylation site. The examination of the oxidative fold-
ing, signal peptide cleavage, glycosylation, dimerization and processing of mutant gp160 into
gp120 and gp41 would provide a better understanding of the role of the N156 glycan during
HIV gp160 or gp120 biosynthesis.
Interestingly, we found an increased infectivity and transmission potential for the HIV-1
gp120 mutants lacking the N230 or N295 glycans. It might not be a coincidence that these N-
linked glycans have been reported to be readily deleted during the course of resistance develop-
ment towards carbohydrate-binding agents (CBAs) [34]. These compounds have been shown
to be potent HIV entry inhibitors by interacting with the glycans on HIV-1 gp120 [35]. CBA
resistance development is associated with the deletion of multiple gp120 N-linked glycans, pre-
dominantly high-mannose-type glycans. As reported by Férir et al., the gp120 N230 and N295
glycans are amongst the most frequently deleted glycans during CBA resistance development
[34]. The increased infectivity and transmission potential of HIV strains lacking the single
N230 or N295 glycans of gp120, as found in our study, might therefore suggest that these
mutations occurred as secondary mutations during CBA resistance development, compensat-
ing for the detrimental effects of the primary CBA resistance mutations on the viral infectivity,
which has already been suggested for the N230 glycan by Hu et al. [36].
In addition to the mutants lacking either 1 N-glycan or 1 disulphide bridge, we also gener-
ated HIV-1NL4.3 mutants lacking the disulphides in combination with their neighboring N-gly-
cans. We analyzed the infectivity of these virus strains and could conclude that the absence of
the disulphide bridges, either in the presence or the absence of the neighboring N-glycan(s),
was invariably highly detrimental for the infectivity of the mutant virus strains. The combined
deletion of both the disulphide bridge and the neighboring N-glycan was therefore never able
to rescue the defect caused by the deletion of the disulphide bridge (data not shown).
The functional properties observed for several N-glycans located close to the disulphide
bridges is intriguing. It has earlier been shown that (co)receptor-induced conformational
changes in gp120 during virus entry are mediated through the oxidoreduction of certain
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disulphide bridges of gp120 by cellular oxidoreductases such as protein disulphide isomerase
(PDI), thioredoxin-1 (Trx1) and glutaredoxin-1 (Grx1) [37–40]. It has been suggested that the
disulphide bridges C119-C205, C126-C196 and C385-C418 are preferentially targeted by these
enzymes [41]. It is interesting to notice that C126-C196 and C385-C418 were both included in
our study because of their close proximity to the N-glycosylation sites containing N197 and
N386, respectively. It might not be a coincidence that these N-glycans were found to have a
crucial role for at least some viral functions. Both glycan deletions (N197Q and N386Q) were
indeed found to have detrimental effects on viral infectivity and in particular on transmission
of DC-SIGN-captured mutant virus particles to CD4+ T cells. These effects could not simply be
attributed to a defective envelope glycoprotein synthesis (>50% gp120/gp41 present in the
mutant virus particle), as was the case for the N156Q mutation in gp120 (<50% gp120/gp41
present in the mutant virus particle).
In addition to the deletion of N-linked glycans neighboring disulphide bridges in gp120, we
have also introduced new N-glycosylation sites in gp120, at positions close to disulphide brid-
ges that are normally disfavored (excluded) for N-glycosylation. The six HIV-1NL4.3 mutants
that were generated are characterized by the addition of an asparagine that could be glycosy-
lated at position -5, -4 or -3 of a cysteine involved in a disulphide bridge in gp120. Two disul-
phide bridges were selected for the generation of these mutants: C296-C331 and C385-C418.
N-glycosylation sites were either introduced upstream of C296 or upstream of C385. It was
found that one of the three mutants with an additional N-glycan upstream of C296 lost its
infectivity. This result was independent of the presence of the N295 glycan that is neighboring
C296 in WT gp120. Strikingly, the three mutants in which a glycosylation site was introduced
upstream of C385 were all found to lack residual infectivity. These findings indicate that the
presence of N-glycans at specific unfavorable positions in gp120, near disulphide bridges, can
be highly detrimental for the functionality of gp120. It might not be a coincidence that the dele-
terious effects of the introduced N-glycans were more pronounced when positioned upstream
of C385. As noted above, this disulphide bridge is targeted by cellular oxidoreductases during
the HIV entry process [41]. Deletion of the neighboring N386 glycan also had detrimental
effects on viral infectivity. Therefore, it might be attractive to hypothesize that the presence or
absence of glycans in close proximity to some disulphide bridges might have a crucial influence
on the accessibility of the disulphide bridge by oxidoreductases. The presence of N-glycans at
unfavorable positions, or the absence of N-glycans at favorable positions near disulphide brid-
ges might therefore affect oxidoreduction-driven conformational changes that are required to
allow efficient entry and transmission of the virus to susceptible CD4+ cells. Thus, in particular,
we might hypothesize that the N197 and N386 glycans fulfill crucial functions during HIV
infection/transmission by regulating the oxidoreduction of the neighboring disulphide bridges
in gp120, which is a crucial step in the viral entry step. However, more research will be needed
to validate this hypothesis.
A similar spatial organization of N-glycans and disulphide bridges was also found for the
HCV envelope glycoprotein E1, and somewhat less pronounced for glycoprotein E2. Although
these envelope glycoproteins have been shown to mediate viral entry in an oxidoreductase-
independent manner, the oxidized versus reduced state of their disulphide bridges has been
shown to be crucial for HCV entry [42]. Fraser et al. demonstrated that a minimum of 1
unbound cysteine has to be present in both E1 and E2 to allow efficient viral infection. They
suggest that these free thiol-groups are obligate to enable acid-induced conformational changes
in E1 and E2, upon receptor binding and subsequent endocytosis of the viral particle. Acidifica-
tion of the endosome may cause free thiol-groups to evoke thiol-disulphide isomerizations,
ultimately leading to the fusion of the viral and endosomal membranes. Therefore, the
observed co-localization of disulphide bridges (or unbound cysteines) and N-glycans in HCV
Co-Localization of N-Glycans and C-C Bridges in HIV-1 gp120
PLOS ONE | DOI:10.1371/journal.pone.0130621 June 29, 2015 19 / 24
E1 (and E2) might be important for the regulation of disulphide bridge formation versus
unbound cysteine residues as well. In contrast to HIV gp120 and HCV E1 and E2, no N-gly-
cans were found in proximity to disulphide bridges in the Ebola glycoprotein GP. Thiol-disul-
phide exchange reactions have, to our knowledge, not been shown to be involved in the Ebola
entry process. Upon endocytosis of Ebola virus particles, acidification induces cleavage of GP
by the cellular proteases Cathepsin B and L [43]. However, this proteolysis on itself is not suffi-
cient to mediate fusion of the viral and endosomal membranes. Therefore, it has been sug-
gested that an additional host cell factor is needed to mediate the conformational changes in
GP which allow membrane fusion [44]. Disulphide reduction has so far not been demonstrated
for the GP of Ebola virus [45].
It would be interesting to examine the occurrence of N-linked glycans near disulphide brid-
ges in the three-dimensional structure of fully glycosylated HIV-1 gp120. This structure has
recently been published by Lyumkis et al. [46] and Kong et al. [33], and was generated using
cryo-electron microscopy and X-ray crystallography, respectively. A careful 3D analysis of the
spatial organization of disulphide bridges and N-glycans in HIV gp120 would contribute to a
better understanding of the role of disulphide bridges and neighboring N-linked glycans in
natively folded HIV-1 gp120, and to better insights in the effect of the introduction of the novel
N-glycosylation sites on the 3D gp120 structure.
Conclusions
We demonstrated that conserved N-linked glycans appear preferentially near, or in close
proximity to, disulphide bridges in HIV-1 gp120, either at asparagines directly neighboring
the involved cysteines or at asparagines located at the C-terminal side of the cysteine. The
deletion of these N-glycans in some cases had significant detrimental effects on viral func-
tions such as infectivity and transmission potential. On the other hand, introduction of N-
glycans at positions in gp120 that seem to be disfavored for N-glycosylation (as evidenced by
the statistically significant absence of glycosylation motifs at these amino acid positions) was
also shown to result in loss of viral infectivity in some mutants. These data indicate that N-
glycans are not spread randomly across gp120 and that their locations are of critical impor-
tance for the integrity of gp120 functions such as the infectivity and transmission potential of
the virus.
Supporting Information
S1 Fig. Probability of finding an N-linked glycosylation site at a position 1–5 amino acids
from a disulphide bridge in HCV E1 (A) and E2 (B). The amino acid sequences of both gly-
coproteins were obtained from NCBI (GenBank ID ABC40379.1 and NCBI Reference
Sequence NP_751921.1, respectively). The allocation of N-glycosylation sites and disulphide
bridges in E1 and E2 was based on publications of Wahid et al. [14] and Krey et al. [15] respec-
tively. The graph shows the relative probabilities of a glycosylated asparagine at 1, 2, 3, 4 or 5
amino acid positions away from the cysteines involved in disulphide bridges. Negative amino
acid positions correspond to positions at the N-terminal site of the cysteine, positive amino
acid positions correspond to positions at the C-terminal site of the cysteine. The striped line
indicates the probablities in case of random distribution of N-glycosylation sites.
(TIF)
S1 Table. Conservation of cysteines involved in disulphide bridges in gp120. a Amino acid
numbering based on the consensus of consensus HIV Env sequences obtained from the align-
ment of consensus sequences, available on the HIV sequence database website [11]. The
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cysteines are presented as pairs, corresponding with disulphide bond-associated cysteines in
native HIV-1 gp120. The level of conservation over a series of 180 HIV-1 (group M) strains is
shown for each cysteine. The HIV Env amino acid sequences of these HIV-1 strains were
obtained from the HIV sequence compendium of 2014, available on the HIV sequence data-
base [11].
(DOCX)
S2 Table. Details on the probability calculations for the co-localization of disulphide brid-
ges and N-glycosylation sites in HIV gp120. Negative amino acid positions correspond to
positions at the N-terminal side away from a conserved cysteine, while positive amino acid
positions correspond to positions at the C-terminal side away from a conserved cysteine. a The
positions and levels of conservation of N-glycans of HIV-1 gp120 were obtained using the N-
glycosite software available on the HIV sequence database website [11], based on an alignment
of consensus sequences (2004) [11]. The alignment contained consensus sequences for HIV-1
subtypes A1, A2, B, C, D, F1, F2, G, H, CRF01-AE, CRF02-AG, CRF03-AB, CRF04-cpx,
CRF06-cpx, CRF08-BC, CRF10-CD, CRF11-cpx, CRF12-BF, and CRF14-BG. The consensus
of consensus sequences and the ancestral sequences were excluded from the analysis. b This
number was obtained as follows: the consensus of consensus HIV Env sequences obtained
from the alignment of consensus sequences [11] consists of a total of 518 amino acids, of which
18 are conserved cysteines and 18 positions are at the -2 position with respect of a conserved
cysteine (= 2 amino acids upstream of a cysteine). In case of random distribution of N-glycans
across gp120, a total of 482 amino acid positions would therefore be available (= 518 minus 18
minus 18). c The conserved cysteines 125 and 130 are separated by only 4 amino acids, imply-
ing that at the +5 position of cysteine 125 and at the -5 position of cysteine 130 no glycan can
be present.
(DOCX)
S3 Table. Oligonucleotide sequences of the primers used for site-directed mutagenesis and
sequencing of gp120.
(DOCX)
S4 Table. Overview of the mutations introducted into HIV-1NL4.3 gp120. Amino acid num-
bering based on the HIV-1 strain HXB2 gp120. For the deletion of a disulphide bridge, one of
the involved cysteines was mutated into an alanine. For the deletion of an N-linked glycan, the
asparagine of the N-glycosylation site was mutated into a glutamine. In order to insert new N-
glycosylation sites, an asparagine was introduced in combination with a serine two amino acid
positions downstream of the newly-introduced asparagine. The insertion of an N-glycan at
positions 291 and 292 was also combined with the simultaneous deletion of the N295 glycan,
as indicated between parentheses.
(DOCX)
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C157A N156Q S291N + E293S (+ N295Q) 
C196A N197Q V292N + I294S (+ N295Q) 
C228A N230Q E293N + N295S 
C331A N241Q G380N + F382S 
C385A N295Q E381N + F383S 
 N332Q F382N + Y384S 
 N386Q  
 2 
Amino acid numbering based on the HIV-1 strain HXB2 gp120. 3 
For the deletion of a disulphide bridge, one of the involved cysteines was mutated into an 4 
alanine. For the deletion of an N-linked glycan, the asparagine of the N-glycosylation site was 5 
mutated into a glutamine. In order to insert new N-glycosylation sites, an asparagine was 6 
introduced in combination with a serine two amino acid positions downstream of the newly-7 
introduced asparagine. The insertion of an N-glycan at positions 291 and 292 was also 8 
combined with the simultaneous deletion of the N295 glycan, as indicated between 9 
parentheses. 10 
 11 
S3 Table. Oligonucleotide sequences of the primers used for site-directed mutagenesis 1 
and sequencing of gp120. 2 
Primer Nucleotide sequence Description 
Mut_C157A_F GGA GAG ATA AAA AAC GCC TCT TTC AAT ATC  Forward mutagenesis primer for C157A 
Mut_C157A_R GAT ATT GAA AGA GGC GTT TTT TAT CTC TCC Reverse mutagenesis primer for C157A 
Mut_C196A_F GCTATAGGTTGATAAGTGCTAACACCTCAGTCATTAC Forward mutagenesis primer for C196A 
Mut_C196A_R GTA ATG ACT GAG GTG TTA GCA CTT ATC AAC CTA TAG C Reverse mutagenesis primer for C196A 
Mut_C228A_F GTT TTG CGA TTC TAA AAG CTA ATA ATA AGA CGT TC Forward mutagenesis primer for C228A 
Mut_C228A_R GAA CGT CTT ATT ATT AGC TTT TAG AAT CGC AAA AC Reverse mutagenesis primer for C228A 
Mut_C331A_F GAG ACA AGC ACA TGC TAA CAT TAG TAG AGC  Forward mutagenesis primer for C331A 
Mut_C331A_R GCT CTA CTA ATG TTA GCA TGT GCT TGT CTC Reverse mutagenesis primer for C331A 
Mut_C385A_F GGGAATTTTTCTACGCTAATTCAACACAACTG Forward mutagenesis primer for C385A 
Mut_C385A_R CAG TTG TGT TGA ATT AGC GTA GAA AAA TTC CC Reverse mutagenesis primer for C385A 
Mut_N156Q_F GAA AGG AGA GAT AAA ACA ATG CTC TTT CAA TAT C Forward mutagenesis primer for N156Q 
Mut_N156Q_R GAT ATT GAA AGA GCA TTG TTT TAT CTC TCC TTT C Reverse mutagenesis primer for N156Q 
Mut_N197Q_F GCTATAGGTTGATAAGTTGTCAGACCTCAGTCATTACACAG Forward mutagenesis primer for N197Q 
Mut_N197Q_R CTG TGT AAT GAC TGA GGT CTG ACA ACT TAT CAA CCT ATA GC Reverse mutagenesis primer for N197Q 
Mut_N230Q_F GCG ATT CTA AAA TGT AAT CAG AAG ACG TTC AAT GGA AC Forward mutagenesis primer for N230Q 
Mut_N230Q_R GTT CCA TTG AAC GTC TTC TGA TTA CAT TTT AGA ATC GC Reverse mutagenesis primer for N230Q 
Mut_N241Q_F GGA ACA GGA CCA TGT ACA CAG GTC AGC ACA GTA CAA TG Forward mutagenesis primer for N241Q 
Mut_N241Q_R CAT TGT ACT GTG CTG ACC TGT GTA CAT GGT CCT GTT CC Reverse mutagenesis primer for N241Q 
Mut_N295Q_F CAC ATC TGT AGA AAT TCA GTG TAC AAG ACC CAA C Forward mutagenesis primer for N295Q 
Mut_N295Q_R GTT GGG TCT TGT ACA CTG AAT TTC TAC AGA TGT G Reverse mutagenesis primer for N295Q 
Mut_N332Q_F GAG ACA AGC ACA TTG TCA GAT TAG TAG AGC AAA ATG G Forward mutagenesis primer for N332Q 
Mut_N332Q_R CCA TTT TGC TCT ACT AAT CTG ACA ATG TGC TTG TCT C  Reverse mutagenesis primer for N332Q 
Mut_N386Q_F GGGAATTTTTCTACTGTCAATCAACACAACTGTTTAATAGTAC Forward mutagenesis primer for N386Q 
Mut_N386Q_R GTA CTA TTA AACA GTT GTG TTG ATT GAC AGT AGA AAA ATT CCC Reverse mutagenesis primer for N386Q 
Mut_V292N/I294S_F CTG AAC ACA TCT AAT GAA TCT AAT TGT ACA AGA  Forward mutagenesis primer for V292N/I294S 
Mut_V292N/I294S_R TCT TGT ACA ATT AGA TTC ATT AGA TGT GTT CAG  Reverse mutagenesis primer for V292N/I294S 
Mut_S291N/E293S_F CAG CTG AAC ACA AAT GTA TCT ATT AAT TGT ACA Forward mutagenesis primer for S291N/E293S 
Mut_S291N/E293S_R TGT ACA ATT AAT AGA TAC ATT TGT GTT CAG CTG Reverse mutagenesis primer for S291N/E293S 
Mut_E293N/N295S_F AAC ACA TCT GTA AAT ATT TCT TGT ACA AGA CCC Forward mutagenesis primer for E293N/N295S 
Mut_E293N/N295S_R GGG TCT TGT ACA AGA AAT ATT TAC AGA TGT GTT Reverse mutagenesis primer for E293N/N295S 
Mut_V292N/I294S/N295Q_F CTG AAC ACA TCT AAT GAA TCT CAG TGT ACA AGA CCC AAC Forward mutagenesis primer for V292N/I294S/N295Q 
Mut_V292N/I294S/N295Q_R GTT GGG TCT TGT ACA CTG AGA TTC ATT AGA TGT GTT CAG Reverse mutagenesis primer for V292N/I294S/N295Q 
Mut_S291N/E293S/N295Q_F CAG CTG AAC ACA AAT GTA TCT ATT CAG TGT ACA AGA CCC Forward mutagenesis primer for S291N/E293S/N295Q 
Mut_S291N/E293S/N295Q_R GGG TCT TGT ACA CTG AAT AGA TAC ATT TGT GTT CAG CTG Reverse mutagenesis primer for S291N/E293S/N295Q 
Mut_I294S_F CAC ATC TGT AGA ATC TAA TTG TAC AAG A Forward mutagenesis primer for I294S 
Mut_I294S_R TCT TGT ACA ATT AGA TTC TAC AGA TGT G Reverse mutagenesis primer for I294S 
Mut_V292N_F CTG AAC ACA TCT AAT GAA ATT AAT TGT Forward mutagenesis primer for V292N 
Mut_V292N_R ACA ATT AAT TTC ATT AGA TGT GTT CAG Reverse mutagenesis primer for V292N 
Mut_F382N/Y384S_F AAT TGT GGA GGG GAA AAT TTC TCA TGT AAT TCA ACA C Forward mutagenesis primer for F382N/Y384S 
Mut_F382N/Y384S_R GTG TTG AAT TAC ATG AGA AAT TTT CCC CTC CAC AAT T Reverse mutagenesis primer for F382N/Y384S 
Mut_E381N/F383S_F TTT AAT TGT GGA GGG AAT TTT TCA TAC TGT AAT TCA AC Forward mutagenesis primer for E381N/F383S 
Mut_E381N/F383S_R GTT GAA TTA CAG TAT GAA AAA TTC CCT CCA CAA TTA AA Reverse mutagenesis primer for E381N/F383S 
Mut_G380N/F382S_F GTT TTA ATT GTG GAA ATG AAT CAT TCT ACT GTA ATT C Forward mutagenesis primer for G380N/F382S 
Mut_G380N/F382S_R GAA TTA CAG TAG AAT GAT TCA TTT CCA CAA TTA AAA C Reverse mutagenesis primer for G380N/F380S 
AV302 [18] CTAATAGAAAGAGCAGAAGACAGTGG Forward sequencing primer 
AV304 [18] ACATGTGGAAAAATGACATGGT Forward sequencing primer 
AV305 [18] GAGTGGGGTTAATTTTACACATGG Reverse sequencing primer 
AV306 [18] TGTCAGCACAGTACAATGTACACA Forward sequencing primer 
AV307 [18] TCTTCTTCTGCTAGACTGCCAT Reverse sequencing primer 
AV308 [18] TCCTCAGGAGGGGACCCAGAAATT Forward sequencing primer 
AV309 [18] CARTAGAAAAATTCYCCTCYACA Reverse sequencing primer 
AV313 [18] TCCYTCATATYTCCTCCTCCAGGTC Reverse sequencing primer 
 3 
S2 Table. Details on the probability calculations for the co-localization of disulphide 1 
bridges and N-glycosylation sites in HIV gp120 2 
 Conserved glycans 
(> 50% conserved) 
Non-conserved glycans 
(< 50% conserved) 
Number of conserved cysteines, which are involved in 
disulphide bridges in gp120 18 
Calculation of the random chance of finding an N-glycan at a position 1, 2, 3, 4 or 5 amino acids away from 
a cysteine involved in a disulphide bridge in gp120, either at the N-terminal or the C-terminal side of the 
cysteine 
Number of N-glycans in gp120a 24 33 
Number of amino acid positions in gp120 that could, in theory, 
be glycosylatedb 
482 482 
Chance of a glycan at one specific position within gp120 24/482 = 0.05 33/482 = 0.07 
Chance of finding a glycan at a position 1, 2, 3 or 4 amino acids 
away from a cysteine, either at the N-terminal or the C-terminal 
side of the cysteine 
18*0.05 = 0.90 18*0.07 = 1.23 
Chance of finding a glycan at a position 5 amino acids away 
from a cysteine, either at the N-terminal or the C-terminal side 
of the cysteinec 
17*0.05 = 0.85 17*0.07 = 1.16 
Actual number of N-glycans at a position 1, 2, 3, 4 or 5 amino acids away from a cysteine involved in a 
disulphide bridge in gp120 
Number of glycans at position -5 away from a cysteine 0 1 
Number of glycans at position -4 away from a cysteine 0 0 
Number of glycans at position -3 away from a cysteine 0 0 
Number of glycans at position -2 away from a cysteine 0 0 
Number of glycans at position -1 away from a cysteine 3 1 
Number of glycans at position +1 away from a cysteine 3 0 
Number of glycans at position +2 away from a cysteine 1 1 
Number of glycans at position +3 away from a cysteine 2 1 
Number of glycans at position +4 away from a cysteine 0 3 
Number of glycans at position +5 away from a cysteine 1 0 
Probability of finding an N-glycan at a position 1, 2, 3, 4 or 5 amino acids away from a cysteine involved in a 
disulphide bridge in gp120, relative to the probability in case of random distribution of N-glycans over 
gp120 
Probability of a glycan at a position -5 away from a cysteine 0 / 0.85 = 0 1 / 1.16 = 0.9 
Probability of a glycan at a position -4 away from a cysteine 0 / 0.90 = 0 0 / 1.23 = 0 
Probability of a glycan at a position -3 away from a cysteine 0 / 0.90 = 0 0 / 1.23 = 0 
Probability of a glycan at a position -2 away from a cysteine 0 / 0.90 = 0 0 / 1.23 = 0 
Probability of a glycan at a position -1 away from a cysteine 3 / 0.90 = 3.3 1 / 1.23 = 0.8 
Probability of a glycan at a position +1 away from a cysteine 3 / 0.90 = 3.3 0 / 1.23 = 0 
Probability of a glycan at a position +2 away from a cysteine 1 / 0.90 = 1.1 1 / 1.23 = 0.8 
Probability of a glycan at a position +3 away from a cysteine 2 / 0.90 = 2.2 1 / 1.23 = 0.8 
Probability of a glycan at a position +4 away from a cysteine 0 / 0.90 = 0 3 / 1.23 = 2.4 
Probability of a glycan at a position +5 away from a cysteine 1 / 0.85 = 1.2 0 / 1.16 = 0 
 3 
Negative amino acid positions correspond to positions at the N-terminal side away from a 4 
conserved cysteine, while positive amino acid positions correspond to positions at the C-5 
terminal side away from a conserved cysteine. 6 
a The positions and levels of conservation of N-glycans of HIV-1 gp120 were obtained using 7 
the N-glycosite software available on the HIV sequence database website [11], based on an 8 
alignment of consensus sequences (2004) [11]. The alignment contained consensus sequences 9 
for HIV-1 subtypes A1, A2, B, C, D, F1, F2, G, H, CRF01-AE, CRF02-AG, CRF03-AB, 10 
CRF04-cpx, CRF06-cpx, CRF08-BC, CRF10-CD, CRF11-cpx, CRF12-BF, and CRF14-BG. 11 
The consensus of consensus sequences and the ancestral sequences were excluded from the 12 
analysis. 13 
b This number was obtained as follows: the consensus of consensus HIV Env sequences 14 
obtained from the alignment of consensus sequences [11] consists of a total of 518 amino 15 
acids, of which 18 are conserved cysteines and 18 positions are at the -2 position with respect 16 
of a conserved cysteine (= 2 amino acids upstream of a cysteine). In case of random 17 
distribution of N-glycans across gp120, a total of 482 amino acid positions would therefore be 18 
available (= 518 minus 18 minus 18). 19 
c The conserved cysteines 125 and 130 are separated by only 4 amino acids, implying that at 20 
the +5 position of cysteine 125 and at the -5 position of cysteine 130 no glycan can be 21 
present.  22 
 23 
S1 Table. Conservation of cysteines involved in disulphide bridges in gp120 1 
Disulphide (cysteine) positions in gp120 of 
consensus sequencea 
Disulphide (cysteine) positions in 
gp120 of strain HIV-1HXB2 
Cysteine 
conservation (%) 
53 54 100.0 
73 74 100.0 
118 119 100.0 
214 205 99.4 
125 126 99.4 
205 196 98.9 
130 131 99.4 
160 157 100.0 
227 218 100.0 
256 247 98.9 
237 228 99.4 
248 239 99.4 
305 296 100.0 
339 331 98.9 
385 378 98.3 
451 445 99.4 
392 385 100.0 
424 418 98.3 
 2 
a Amino acid numbering based on the consensus of consensus HIV Env sequences obtained 3 
from the alignment of consensus sequences, available on the HIV sequence database website 4 
[11]. 5 
The cysteines are presented as pairs, corresponding with disulphide bond-associated cysteines 6 
in native HIV-1 gp120. The level of conservation over a series of 180 HIV-1 (group M) 7 
strains is shown for each cysteine. The HIV Env amino acid sequences of these HIV-1 strains 8 
were obtained from the HIV sequence compendium of 2014, available on the HIV sequence 9 
database [11]. 10 
 11 

